Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.03 -0.50%

-$0.14 today

Market cap
$465.03M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 8.33M

Average 1.08M

CAPR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Capricor Therapeutics, Inc.NASDAQ: CAPR

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $18.92M a year earlier. Trailing-twelve-month cost of revenue was $42.41M.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $10.6M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$42.41M-26.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How CAPR compares with its peers on the latest reported figures

  • CAPR's LTM Mar 2026 cost of revenue of $42.41M is the 3rd highest of the 10 companies compared; the peer median is $4.46M.
  • Its year-over-year change of -26.6% is the lowest of 7, against a peer median of +104.1%.
CAPR Competitors Peer median
Cost of Revenue for CAPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$821.4M +102.3%+84.7%37.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$180.19M +250.5%+17.1%17.9%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M -26.6%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.05M ——698.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M +44.2%+4.3%1.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.46M +106.0%—6.2%
PEPGPepGen Inc.LTM Mar 2026$1.72M +351.6%——
SLDBSolid Biosciences Inc.LTM Mar 2026$781K +91.9%——
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$590K ———
DYNDyne Therapeutics, Inc.LTM Jun 2026$521K ———
Peer median (excluding CAPR) $4.46M+104.1%+17.1%17.9%

Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue244.9K2.55M25.18M22.27M0
Cost of Revenue021.82M36.45M49.97M0
Gross Profit244.9K(19.27M)(11.27M)(27.7M)0
Gross Margin100.0%-755.1%-44.8%-124.4%—
Research & Development13.57M21.82M36.45M49.97M84.45M
Selling, General & Admin7.61M10.43M12.81M14.87M22.75M
Operating Expenses21.18M10.43M12.81M14.87M108.14M
Depreciation & Amortization245.7K533.13K1.07M1.43M1.89M
EBITDA(19.78M)(28.49M)(21.22M)(39.04M)(100.11M)
EBITDA Margin-8075.5%-1116.5%-84.3%-175.3%—
Operating Income(20.94M)(29.7M)(24.08M)(42.56M)(108.14M)
Operating Margin-8549.9%-1163.9%-95.6%-191.1%—
Interest Income0521.53K1.73M2.2M6.26M
Interest Expense00003.05M
Other Income / Expenses915.92K677.85K1.79M2.1M3.1M
Income Before Tax(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Pre-Tax Margin-8175.9%-1137.4%-88.5%-181.7%—
Income Tax Expense00000
Net Income(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Net Margin-8175.9%-1137.4%-88.5%-181.7%—
EPS (Basic)(0.87)(1.18)(0.83)(1.15)(2.26)
EPS (Diluted)(0.87)(1.18)(0.83)(1.15)(2.26)
Weighted Avg Shares23.09M24.55M26.78M35.22M46.48M
Weighted Avg Shares (Diluted)23.09M24.55M26.78M35.22M46.48M

Capricor Therapeutics, Inc.

NASDAQ:CAPR

Intrinsic Alpha fair value

Locked

Current Price

$8.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.